A phase II trial of weekly irinotecan in cisplatin-refractory esophageal cancer

Anticancer Research

Volumn 27, Issue 4 C, 2007, Pages 2845-2848

  Burkart, Christof ^a   Bokemeyer, Carsten ^a   Klump, Bodo ^a   Pereira, Philippe ^a   Teichmann, Reinhard ^a   Hartmann, Jörg Thomas ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Chemotherapy; Esophageal cancer; Irinotecan; Refractory

Indexed keywords

ATROPINE; CISPLATIN; IRINOTECAN; LOPERAMIDE;

ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; CANCER GRADING; CANCER SURVIVAL; CHOLINERGIC ACTIVITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; COUGHING; DIARRHEA; DIZZINESS; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; DYSPNEA; ESOPHAGUS CANCER; FATIGUE; FEMALE; FEVER; HUMAN; HYPERCALCEMIA; INFECTION; LEUKOPENIA; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; PAIN; PARESTHESIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SURVIVAL TIME; TREATMENT RESPONSE; VOMITING; WORLD HEALTH ORGANIZATION;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; CARCINOMA, SQUAMOUS CELL; CISPLATIN; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, NEOPLASM; ESOPHAGEAL NEOPLASMS; FEMALE; HUMANS; MALE; MIDDLE AGED;

EID: 34547817775     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Blot WJ and McLaughlin JK: The changing epidemiology of esophageal cancer. Semin Oncol 26: 2-8, 1999.
2. Axelrad AM and Fleischer DE: Oesophageal tumors. In: Sleisinger and Fordtrans Gastrointestinal and Liver Disease. Feldmann M, Scharschmidt BF and Sleisinger MH (eds.). WB Saunders, Philadelphia, pp. 540-554, 1998.
3. Enzinger PC, Ilson DH and Kelsen DP: Chemotherapy in esophageal cancer. Semin Oncol 26: 12-20, 1999.
4. Bleiberg H, Conroy T, Paillot B, Lacave AJ, Blijham G, Jacob JH, Bedenne L, Namer M, De Besi P, Gay F, Collette L and Sahmoud T: Randomised phase II study of cisplatin and 5-fluorouracil (5-FU) versus cisplatin alone in advanced squamous cell oesophageal cancer. Eur J Cancer 33: 1216-1220, 1997.
5. De Besi P, Sileni VC, Salvagno L, Tremolada C, Cartei G, Fosser V, Paccagnella A, Peracchia A and Fiorentino M: Phase II study of cisplatin, 5-FU, and allopurinol in advanced esophageal cancer. Cancer Treat Rep 70: 909-910, 1986.
6. Iizuka T, Kakegawa T, Ide H, Ando N, Watanabe H, Tanaka O, Takagi I, Isono K, Ishida K and Arimori M: Phase II evaluation of cisplatin and 5-fluorouracil in advanced squamous cell carcinoma of the esophagus: a Japanese Esophageal Oncology Group Trial. Jpn J Clin Oncol 22: 172-176, 1992.
7. Pozzo C, Barone C, Szanto J, Padi E, Peschel C, Bukki J, Gorbunova V, Valvere V, Zaluski J, Biakhov M, Zuber E, Jacques C and Bugat R: Irinotecan in combination with 5-fluorouracil and folinic acid or with cisplatin in patients with advanced gastric or esophageal-gastric junction adenocarcinoma: results of a randomized phase II study. Ann Oncol 15: 1773-1781, 2004.
8. Ilson DH: Phase II trial of weekly irinotecan/cisplatin in advanced esophageal cancer. Oncology (Williston Park) 18: 22-25, 2004.
9. Hsiang YH, Hertzberg R, Hecht S and Liu LF: Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J Biol Chem 260: 14873-14878, 1985.
10. Schneider E, Hsiang YH and Liu LF: DNA topoisomerases as anticancer drug targets. Adv Pharmacol 21: 149-183, 1990.
11. Ilson DH, Saltz L, Enzinger P, Huang Y, Kornblith A, Gollub M, O'Reilly E, Schwartz G, DeGroff J, Gonzalez G and Kelsen DP: Phase II trial of weekly irinotecan plus cisplatin in advanced esophageal cancer. J Clin Oncol 17: 3270-3275, 1999.
12. Hecht JR, Mand P and Lee R: A phase II trial of irinotecan (CPT-11) in patients with adenocarcinoma of the oesophagus and gastric cardia. Proc Am Soc Clin Oncol 18: (abstr. 1100) 1999.
13. Miller AB, Hoogstraten B, Staquet M and Winkler A: Reporting results of cancer treatment. Cancer 47: 207-214, 1981.
14. WHO Handbook for reporting results of Cancer Treatment. WHO offset publication No. 48 Neoplasma: 37-46, 1980.
15. Simon R: Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10: 1-10, 1989.
16. Kaplan EL and Maier P: Non-parametric estimation from incomplete observations. J Am Stat Assoc 53: 457-481, 1958.
17. Tsai JY, Iannitti D, Berkenblit A, Akerman P, Nadeem A, Rathore R, Harrington D, Roye D, Miner T, Barnett JM, Maia C, Stuart K and Safran H: Phase I study of docetaxel, capecitabine, and carboplatin in metastatic esophagogastric cancer. Am J Clin Oncol 28: 329-333, 2005.
18. Morgan-Meadows S, Mulkerin D, Berlin JD, Kim K, Bailey H, Saphner T, Jumonville A, Hansen R, Ahuja H, McFarland T and Thomas JP: A phase II trial of gemcitabine, 5-fluorouracil and leucovorin in advanced esophageal carcinoma. Oncology 69: 130-134, 2005.
19. Khushalani NI, Leichman CG, Proulx G, Nava H, Bodnar L, Klippenstein D, Litwin A, Smith J, Nava E, Pendyala L, Smith P, Greco W, Berdzik J, Douglass H and Leichman L: Oxaliplatin in combination with protracted-infusion fluorouracil and radiation: report of a clinical trial for patients with esophageal cancer. J Clin Oncol 20: 2844-2850, 2002.
20. Ajani JA, Baker J, Pisters PW, Ho L, Mansfield PF, Feig BW and Charnsangavej C: CPT-11 plus cisplatin in patients with advanced, untreated gastric or gastroesophageal junction carcinoma: results of a phase II study. Cancer 94: 641-646, 2002.
21. Muhr-Wilkenshoff F, Hinkelbein W, Ohnesorge I, Wolf KJ, Riecken EO, Zeitz M and Scherubl H: A pilot study of irinotecan (CPT-11) as single-agent therapy in patients with locally advanced or metastatic esophageal carcinoma. Int J Colorectal Dis 18: 330-334, 2003.